Moderna’s Shares Surge Following Claims of 94.5% Efficacy for its COVID-19 Vaccine
Moderna claims that its COVID-19 vaccine candidate, mRNA-1273 has met the primary endpoint of the Phase 3 COVE study with a staggering efficacy of almost 95%, surpassing the bar set …
Read More